PLURISTEM LIFE Science (PLRS) Nächster Verdoppler auf meiner Liste! - 500 Beiträge pro Seite

[the key]

US-OTCBB-Tickersymbol: PLRS
Aktueller US-Kurs : $0.028
1.KZ: $.056
Chart: http://stockcharts.com/gallery/?PLRS
News: http://finance.yahoo.com/q?s=PLRS.ob
Website: www.pluristem.com
US Intraday

US 3Monatschart


Pluristem Life Systems, Inc. (OTCBB: PLRS) biotechnology company is dedicated to the commercialization of allogeniec cell therapy products for the treatment of severe blood, cardiovascular and autoimmune disorders. The first product planned by the company is dedicated to resolving the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood (UCB). The Company owns GMP early stage facilities and an animal house to conduct research, development and manufacturing of its products.

Pluristem has discovered and patented a process to grow and expand Adult Mesenchymal and Hematopoietic Stem Cells (MCS, HSC). Cell expansion is executed in an environment that mimics natures microstructure of bone marrow and does not include the supplemented growth factors of cytokines. It is for this reason that Pluristem's Technology is to the best of their knowledge the most efficient and safe way to grow Mesenchymal and Hematopoietc stem cells on a production scale for cell therapy products. The first product targets a critical global shortfall of matched tissue for bone marrow transplantation (BMT).

Corporate History of Pluristem

The attached information has been prepared by Pluristem using its best efforts to realistically and factually present the information contained. However, subjective opinion, dependence upon factors outside Pluristem's control and outside information sources unavoidably dictate that Pluristem cannot warrant the information contained to be exhaustive, complete or sufficient. In addition, many factors can affect Pluristem's plans which could significantly alter the results intended by Pluristem, rendering Pluristem's plans unattainable or substantially altered. Therefore, interested readers should conduct their own assessment and consult with their own professional advisors prior to making any investment or other decisions. Readers should also review the risk factors set out in Pluristem's latest 10-KSB as filed on Edgar with the SEC.

This corporate history does not constitute a prospectus or public offering for financing, and no guarantees are made or implied with regard to the success of Pluristem's proposed business.

Pluristem began its business mission in 2001 as A.I. Software, Inc. with an emphasis on the use of artificial intelligence in computer programming technology on the Internet, in robotics, and in the gaming industry.

In early 2003 , the Company's Board conducted an in-depth analysis of its corporate history and the future prospects for software development companies. To better protect stockholder interests and provide ongoing appreciation, it was decided to concurrently pursue initiatives in the biotech industry as an extension of its software development business.

I n May of 2003, the Company entered into an exclusive License Agreement with Weizmann Institute of Science, and the Technion-Israel Institution of Technology to acquire an exclusive license for an innovative stem cell expansion technology. Included with this acquired technology was the scientific basis for a stromal cell bioreactor. The bioreactor has since been developed into a unique 3D system that enables ex-vivo expansion of Hematopoietic Stem Cell (HSC) populations in a microenvironment resembling the architecture of natural bone marrow.

Fully developed, this technology is intended to offer novel solutions making procedures like bone marrow transplants and other methods of cell therapy more accessible to patients suffering from leukemia, lymphoma, myeloma and a broad range of complicated diseases and disorders.

On June 10, 2003, in order to better develop this exclusively licensed technology, the Company purchased 100% of the issued and outstanding shares of Pluristem Ltd., a research and development company based in Israel.

The acquisition of the stem cell technology license, the bioreactor and process, and the Israeli-based bio-research company was immediately recognized by corporate management as a coup that would radically change the Company's original mission.

As of July 1, 2003 , the Company suspended its efforts to further develop artificial intelligence in computer programming and changed its name to Pluristem Life Systems, Inc.

Shortly after its official name change Pluristem branded its first principal technology - the stromal cell bioreactor – as the '3-D' PluriX Bioreactor ™, and immediately commenced contacting research centers and cord blood banks to establish cooperative relationships for future business development. Pluristem believed it was ushering in a breakthrough in stem cell expansion technology, principally the expansion of cord blood HSC.

Subsequently in July 2003, Pluristem announced that it had crossed a milestone in its stem cell expansion technology by successfully implanting stromal cells into its bioreactors, creating an environment that would encourage stem cells to self-renew without differentiation. This would mark an important step toward expanding (growing) stem cells from Umbilical Cord Blood (UCB) blood for bone marrow transplants in adults.

By late 2003 , with key technology and licenses in hand, Pluristem had not only embarked on an intensive research and development agenda, but had also begun assembling an impressive roster of leading medical specialists and scientists.

Since total expenditures on bone marrow transplants worldwide are currently in the range of $5 billion with hundreds of thousands of lives at stake, Company scientists researched UCB as a new and very effective source of readily available stem cells that could be used in bone marrow transplants.

Traditional bone marrow transplants are often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. Since a bone marrow transplant relies on the availability of cord blood, stem cells from a matched donor are transplanted to replace the blood system of the patient. The transplant requires donors with a very close bone marrow match to the recipient, but only about 30% of patients in need of transplants can find a suitable donor. Since the collection of cord blood from the donor is simple, non-invasive and the extracted stem cells are highly tolerant, cord blood transplants have received tremendous attention.

However, due to the small volume of blood collected from umbilical cords, cord blood transplants have been limited to infants and children weighing less than 100 lbs. The need to develop expansion technology has become imperative in order to reach a viable option for bone marrow transplants for all ages. In Pluristem's planned product PLX II, the ‘3-D' PluriX(TM) bioreactor could utilize expanded HSC found in UCB into quantities large enough for transplantation in more than one adult. HSC are exclusively required for bone marrow transplants and are the only cells that can reconstitute the hematopoietic system following bone marrow transplantation. These vital early stage stem cells have the distinct capacity to self-renew, expand and differentiate or evolve into different types of blood cells.

In April 2004 , Pluristem revealed the laboratory results of its proprietary '3-D' PluriX(TM) bioreactor. Unlike conventional two-dimensional (i.e., flat) culturing, the unique ability of the “3-D' PluriX(TM) bioreactor is to create a three-dimensional microenvironment that closely resembles the structure and function of the body's bone marrow environment. The “3-D' PluriX(TM) bioreactor, consisting of a stromal cell culture, provides the optimal environment to support and maintain HSC.

I n August 2004 , Pluristem announced an interdisciplinary collaboration with the Israel Institute of Technology to develop an innovative biodegradable 'scaffolding' technology that would further enhance the rate of growth of HSC in the Company's ‘3-D' PluriX(TM) Bioreactor. This collaboration brought top scientists together to develop Pluristem's next planned phase: the PLX III platform technology for expanding stem cells collected from umbilical cord. The research program combined the efforts of leading scientists from the Technion Faculties of Medicine, Chemistry, Material Engineering and Biotechnology, and the Pluristem research and development team. This promising new approach is intended to significantly improve the success rate of bone marrow transplantations using HSC from cord blood.

Between August 2004 and early 2005 investors showed confidence in Pluristem's progress with additional infusions totaling $5 million.

In March of 2005 , the Company's efforts were validated in a major milestone achievement when the Company received a 'Notice of Allowance' from the U.S. Patent and Trademark Office providing broad coverage of its proprietary stem cell expansion technology. This patent allowance was filed to protect the concept and the mechanism of action of the ‘3-D' PluriX(TM) bioreactor. It provides important validation of Pluristem's technology which mimics the three dimensional human bone marrow environments in order to achieve significant stem cell replication without the utilization of artificial substances.

"This U.S. patent allowance represents a significant milestone for the Company. We are actively moving ahead in our lab as we work to change the world of bone marrow transplants. Stem cell expansion has the potential to make bone marrow transplants a most effective therapy while also making it available to a broader patient population," stated Dr. Shai Meretzki , the founder of Pluristem.

I n October 2005 , the Company received final issuance of the United States patent added to similar intellectual protection in New Zealand, Australia, and South Africa placing Pluristem in a key position for the $5 billion bone marrow transplant market.

By year's end 2005 , Pluristem was on its way to developing, producing and marketing stem cell products for cell regenerative therapy. Pluristem's platform for expanding stem cells offers breakthrough technology and multiple product opportunities in many therapeutic areas. It's patented ‘3-D' PluriX(TM) bioreactor is expected to give the Company a considerable growth advantage.

In January of 2006 , Pluristem announced that the Company has formulated a cell graft to provide an efficient alternative to the standard procedure of bone marrow transplantation. Initial results of an animal model study were promising using the company's innovative adjuvant cell graft therapy product known as PLX-I. PLX-I uses Mesenchymal Stromal Cells (MSC) in bone marrow transplants along with UCB samples to achieve the breakthrough solution that improved engraftment of the blood-producing HSC. The preliminary results suggest that the use of MSC in combination with HSC derived from UCB can improve the treatment of blood disorders and could potentially save the lives of million of people.

The mixture of MSC cells is being transplanted into a subject with HSC as a co-cultured graft. This unique feature is expected to award Pluristem with an additional advantage over its competitors - excellent engraftment. When presented to the bone marrow of a transplanted patient as a co-cultured graft rather than as HSC only, a better engraftment of the donor HSC is anticipated. This observation was published by several leading authors and initially demonstrated to be effective in initial animal model studies by the Company.

Dr. Ora Burger , Vice President of Development, stated, "Pluristem has literally reinvented the process of hematopoietic stem cell expansion and engraftment through its novel approach. The field of stem cell expansion technology and bone marrow transplants is ripe for new approaches that hold the potential to save millions of lives. Our laboratory in Haifa is a hot-bed of activity. We expect to gain worldwide recognition acting as an incubator for a host of stem cell expansion technologies."

"This breakthrough starts to move us from the research phase to the development phase. As announced, we plan to bring the successful animal model studies to the clinic as expeditiously as possible. The Company plans on presenting its findings in a number of scientific conferences throughout the year, furthering validation of these technological processes while we continue to go on the road to bring our new message to the investment community,” stated Zami Aberman , CEO.

In February 2006 , the Company reached yet another milestone when it announced that a patent application had been filed with the U. S. Patent and Trademark Office for a new procedure expanding HSC and early progenitor cells from cord blood gathered from non- selected mono-nuclear cells (MNC) of the cord blood. Pluristem's expansion protocol is intended to overcome both hurdles by using cord blood from non-selected MNC to fuel the enrichment process.

Dr. Ora Burger , Vice President of Development, stated, "The existing stem cell separation and selection process is not conducive to growing industry requirements. What we expect to become is the industry standard."

In March 2006 , Pluristem announced that the Company is changing its business strategy. Instead of licensing the use of the proprietary bioreactor-enabling technology, the Company plans to develop cell therapy products that can be marketed on a for-sale basis. The first products are expected to be cell grafts that will provide an efficient and superior alternative to the traditional bone marrow transplant procedure.

In May 2006 , the Company filed another patent application with the U. S. Patent and Trademark Office for the PLX-I stem cell therapy product.

In July 2006 , Pluristem announced promising initial results of an animal model study using the adjuvant cell therapy PLX-I product. The results showed that when human UCB samples were transplanted together with PLX I into NOD SCID mice, the amount of engrafted cells was from 2-4 times greater than when transplants were carried out with UCB samples lacking PLX I.

"The significance of the trial is that we have shown that sufficient engraftment is possible with the limited number of hematopoietic stem cells available in a single portion of umbilical cord blood. This paves the way towards using umbilical cord blood instead of bone marrow transplants for adult patients as well as improving the effectiveness of engraftments in child patients and shortening recovery times. If additional animal studies and human clinical trials prove equally successful, PLX-I could lead to wider use of bone marrow transplants in various types of blood cancer. Nearly 100,000 people could benefit from this treatment annually,” stated Zami Aberman , CEO.

Mission Statement

Pluristem Life Systems, is a life sciences driven company developing a proprietary stem cell expansion technology for the treatment of severe blood disorders.

The practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations, thus Pluristem has made a strategic decision to work only with adult stem cells. The first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation (BMT), since BMT is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases.

Umbilical Cord Blood vs. Bone Marrow Transplants

The problems with using umbilical cord blood in place of bone marrow: there usually aren't enough blood-producing stem cells in the cord blood whereas the blood from an average baby's umbilical cord usually provides less than a third of the amount needed for the average adult patient, and the UCB engrafts later compared to a traditional bone marrow transplant.

The Solution: PLX-I

Pluristem has discovered and patented a technology process that can solve these UCB problems. By growing and expanding mesenchymal stem cells (MSC) from Placenta, their PLX-I product has been proven to increase the UCB stem cells effectiveness by 2-4 times and increase the engraftment rate.

Using this technology, PLX-I has been developed as an allogeneic product. It is based on supplementing the umbilical cord blood cells with supportive cells that will improve the effectiveness of engraftments and shorten recovery times. After production, PLX-I is stored “ready to use”; the patient does not have to wait several weeks for stem cells to grow in culture while his life is at risk. Once a matched cord blood is found, the PLX-I is ready for use immediately on arrival at the hospital. PLX-I is injected into the patient venous just a few hours before the UCB injection to improve the engraftment. Additionally, it may be possible to “boost” engraftment of the UCB HSCs by multiple potential PLX-1 injections.

They plan to use Mesenchymal cells to further enhance the engraftment of HSC following a bone marrow transplant. MSCs are the founding cells of many tissues like bone, fat and cartilage. They are progenitors cells that have strong anti-inflammatory properties and can regenerate and repair damaged tissue. When MSCs receive appropriate biochemical and biomechanical signals they can differentiate into various connective tissues such as bone, muscle, fat, tendon, ligament, cartilage and bone marrow stroma. MSCs also have low immunogenicity and are not rejected by the patient immune system, and therefore do not require HLA matching.

Market Competition

Pluristem's cell expansion technology is the only stem cell technology that produces all-natural products. Pluristem does not use growth hormones or other synthetic materials such as recombinant cytokines in order to accelerate the proliferation of the stem cells, or in order to repress the differentiation of these cells.

Their competitors continue to use chemical additives in their cultures even though many in the scientific community believe that the addition of these chemicals may cause genetic instability in the stem cells and other unwanted side effects in the long run.

Another key advantage that the PLX-I product offers over the competitors' systems is that it is stored "ready to use". There is no waiting several weeks for the stem cells to grow in culture while the patient is languishing.

Their primary PLX-I competitors in treating blood disorders are ViaCell Inc. (NASDAQ: VIAC) and Gamida-Cell Ltd. In other MSC based therapeutic products the main competitor is Osiris Therapeutics Inc. (NASDAQ: OSIR).

Management Team

- Zami Aberman – President & CEO- Has held Chief Executive and Chairman held positions in high tech companies in Israel, USA, Europe, Japan and Korea.
- Yossi Keret –CFO experienced with NASDAQ-listed companies, start-ups, and CPA formerly with an Ernst & Young affiliate.
- Dr. Shai Meretzki – Pluristem Founder, CTO, PhD Biotechnology, Chemical Engineer, and inventor of PluriX™ technology.
- Dr. Ora Burger – VP Research & Development, PhD Biotechnology, experienced in development of biotech products.

Scientific Advisory Board

Prof. Jacob M. Rowe, MD – Head of Scientific Advisory Board, leading BMT specialist, Chief of Haematology & Bone Marrow Department at Rambam Medical Center, Haifa. Acted as Director of Clinical Services in the Hematology Unit at the University of Rochester Medical Center, NY.

Prof. Arnon Nagler, MD - Leading BMT specialist, Chief of Haematology & Bone Marrow Department, Sheba Medical Center, Tel Aviv.

Prof. Edwein M. Horwitz, MD, PhD - Leading Mesenchymal Cell Therapy specialist, Stem Cell Transplantation and Experimental Hematology at St. Jude Children's Research Hospital, Memphis TN

Dr. Avinoam Kaduri - Former Director of Research & Pharmaceutical Development, Serono, Chairman of the European Organization of Biotechnology Companies.

Dr. Avi Treves - Specialist in stem cell-based translational development, Chief of Cancer Research Center, Sheba Medical Center, Tel Aviv

CONTACT INFORMATION

MATAM Tech Park, Bldg. 20
Haifa 31905, Israel.
Tel : [phone]
Fax : [phone]
E-Mail : [e-mail]

[waxweazle]

HAb mir welche geholt morgen könnte da einiges gehen..
TIP immer in den USa kaufen da Volumen höher und nicht über Pari

[the key]

Antwort auf Beitrag Nr.: 24.691.705 von waxweazle am 17.10.06 22:30:38

PLRS wird sowieso nur in den USA gehandelt so weit ich weiß.
Mal gespannt was geht.

[waxweazle]

Antwort auf Beitrag Nr.: 24.693.357 von the key am 17.10.06 23:51:27

Hab ich gefunden wenn das so ein trifft wow


PLRS from lebed fwiw (10/16):

Before reading my following analysis, please remember not to trust my research. Do your own research. My information may not be completely accurate.

PLRS today was the most active stock in the entire market!!!

PLRS traded 112,883,032 shares and finished the day up $0.002 to $0.023.

I think tomorrow will be the day where we see PLRS start breaking out. By Wednesday I think we will have a huge amount of momentum.

PLRS raised a total of $3MM from convertible debentures.

The debenture holders are able to convert to shares at a price of 75% the volume weighted average price of PLRS stock for the past 20 trading days.

Therefore, the price has been sitting at about $0.02 for the past 20 days. 75% of $0.02 is $0.015. This means they have been converting to shares at $0.015 and selling them at $0.023 for a profit of $0.008.

From what I understand, $1MM of the debentures were converted prior to today. I also understand that another $1MM are in friendly hands. Therefore, this means that at the beginning of today there was $1MM in debentures that needed to be converted and sold.

At a price of $0.015, these $1MM in debentures equal about 66.7 million shares. PLRS traded 112.9 million shares today.

If you factor in that many trades are double printed, we could take 50% of 112.9 million and estimate that 56.45 million shares were converted today. This means there is still another 10.25 million left that need to be converted and sold.

If tomorrow morning we trade another 20 million shares, I believe all of the selling will be done and PLRS will explode.

Prior to the recent registration statement, PLRS had 63.7 million shares outstanding. If we figure that all $3MM gets converted at $0.015, this will add another 200 million to the shares outstanding for a total of 263.7 million.

263.7 million shares at $0.023 gives PLRS a market cap of $6 million!!!

VIAC is $5.19 with a $200 million market cap.

STEM is $2.49 with a $194 million market cap.

ASTM is $1.36 with a $163 million market cap.

If PLRS becomes a 10-bagger and goes to $0.23 the market cap will still only be $60 million!!!!!

I personally believe that PLRS has much more promising technology than VIAC, STEM and ASTM!!!!!

Therefore, even at $0.23, I believe PLRS would still be undervalued!!!!!

Now you understand why I believe PLRS will become our biggest percentage gainer of the year!!!!!

Remember that I could be wrong about everything and PLRS could go to zero. You could lose all of your money in this stock. Don't invest based on any information I give you.

[joelu]

uiiiiiiiiiiiiiii, sehr interessant. hätte nicht gedacht, dass da soviel potential hintersteckt!!!

zumindestens phantasie!!!!


aber merke: truth is stronger than fiction.

die phantasei trägt das ding nur kurz. vielelicht reicht es aber trotdem für 0,05$....

[the key]

Pluristem Upgrades Manufacturing Facilities to Enable Production of First Biological Product for Phase I Clinical Trials

Wednesday, October 18, 2006 07:30 ET

HAIFA, Israel, Oct 18, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBB: PLRS) announces they have completed upgrading and restructuring their manufacturing facilities to enable the production of their first biological product PLX-I for Phase I clinical trials. The manufacturing facilities include thirteen units of 7000 square feet total and include five clean room units of 3000 square feet total. Upon FDA approval, the facilities could support production and shipping of up to 50 doses of PLX-I per day worth more than $500,000.

Zami Aberman, Pluristem CEO states, "PLX-I can be used for the treatment of blood disorders and it could also be helpful in additional clinical indications like autoimmune disorders or cardiovascular diseases. It is a very valuable product and we have made a strategic decision to control the production in-house. Handling the product ourselves gives us a distinct advantage when these cross application situations arise. And we have further determined that to assist us in successful Phase I clinical trials and the ultimate approval by the FDA, we have upgraded and restructured as a GMP Compliance facility. GMP Compliance is a set of regulations set forth by the FDA to help ensure that various products for human use are safe and effective. GMP regulations address sanitation, process validation, equipment and document traceability, and personnel qualification. We are also working to become completely GMP compliant to further assure the future successful production and market acceptance of PLX-I."

[biggmoney]

Subject:PLRS Lebed.biz Alert - 1PM Tomorrow and Friday Before the Open!!!


PLRS traded perfectly today!!!

By PLRS hitting $0.032 and then closing at $0.0271, it tells me that all of the daytraders have taken their profits and sold.

With the convertible debenture selling done and the daytraders out, I believe tomorrow could be an explosive day!!!

I will be meeting with PLRS at 11:30AM tomorrow. PLRS will be giving a presentation to hedge funds that have invested into the company. As soon as the meeting is over, probably around 1PM, I will be sending out an alert going over everything I learned at the meeting!

My big PLRS report that I have been writing for the past week will be coming out Friday morning before the open.

Make sure you are around tomorrow at 1PM and Friday before the open. You do not want to miss these upcoming alerts.

TRUST ME... after reading these alerts, you will finally understand why I am so excited about PLRS!!!!!

[lowkatmai]

Antwort auf Beitrag Nr.: 24.713.568 von biggmoney am 19.10.06 06:53:08

Hi,
war ja bislang (noch) nix hier.

Bin durch ein Amiboard auf PLRS aufmerksam geworden.

Mal schauen ich ich einsteige. Oder ist das nur ein riesiges Gepushe durch Lebedd. So nennt sich der Kollege jedenfalls.


l

[the key]

Antwort auf Beitrag Nr.: 24.734.349 von lowkatmai am 20.10.06 09:17:35

Dann warte mal auf 15.30 Uhr

Lebed Push kommt erst heute!!!

[lowkatmai]

Antwort auf Beitrag Nr.: 24.740.047 von the key am 20.10.06 13:23:38

Hi,

"Dann warte mal auf 15.30 Uhr

Lebed Push kommt erst heute!!! "



und was war jetzt um 15:30? Kam da irgendwas?

Kursrelevant scheint es ja nicht gewesen zu sein.

l

[the key]

Antwort auf Beitrag Nr.: 24.747.405 von lowkatmai am 20.10.06 18:12:41

Jo da kamen die vesprochenen Lebed News.
Allerdings wohl erst für die Abonnenten.
Bleibe hier weiterhin am Ball...höre hier Gerüchte über FDA News nächste Woche

[the key]

Antwort auf Beitrag Nr.: 24.691.528 von the key am 17.10.06 22:19:01

[the key]

Antwort auf Beitrag Nr.: 24.753.645 von the key am 21.10.06 01:41:50

SK $ .026

[the key]

SK $ .029

[lowkatmai]

Hi,

haben wohl nicht den gewünschten Effekt gebaht, die


"Jo da kamen die vesprochenen Lebed News."


Heute steige ich hier ein. Denke bei der MK geht was.

l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.840.660 von lowkatmai am 25.10.06 11:48:26

gebaht

GEHABT!!

Schei.. Legathenie


l

[the key]

Antwort auf Beitrag Nr.: 24.840.660 von lowkatmai am 25.10.06 11:48:26

Ein bißchen mehr geduld als 4 Tage sollte man schon aufbringen.

Naja das sind wohl mal wieder die jungen wilden,bei dennen es nicht schnell genug gehen kann

Lies mal die letzten News dann verstehst Du vielleicht,warum der Kurs in den vorigen Tagen nicht aus den Pötten kam.
Die Convertibles sind aber nun abgeschlossen.....

PLURISTEM COMPLETES CONVERSION OF OUTSTANDING CONVERTIBLE DEBENTURES



98% Of the$3 Million in Convertible Debentures Issued in April 2006 Have Been Converted To Common Stock



HAIFA, Israel- October 24, 2006 - Pluristem Life Systems, Inc. (OTCBB: PLRS) today announced that it has completed the conversion to common stock of 98% of the $3,000,000 in convertible debentures that were issued on April 3, 2006 . The total number of outstanding common shares is now about 254 million shares.



Zami Aberman, CEO of Pluristem, stated, "This development allows us considerably more financing flexibility. As a condition of the April financing, we were prevented from pursuing certain types of financing arrangements and our assets were encumbered as collateral security for repayment of the debentures, until over 75% of the debentures were converted to common stock. Now that the vast majority of the debentures have been converted into stock, our assets are no longer encumbered and we are no longer restricted in the type of financing arrangements that we can make. In addition, our balance sheet no longer will show the converted debenture proceeds as a liability. "



About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilize adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations

www.pluristem.com/default.asp



Safe Harbor Statement



This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: that our facilities enable the production of the first biological product PLX-I for Phase I clinical trials; that our facilities could support production and shipping of up to 50 doses of PLX-I per day worth $500,000 per day, that

PLX-I can be used for the treatment of blood disorders and it could also be helpful in additional clinical indications like autoimmune disorders or cardiovascular diseases, that





we intend to control the production ourselves; that our production will give us a distinct advantage; that we are working to become completely GMP compliant; that we expect our first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation, and our first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unable to attain GMP compliance; our facilities may not be capable of controlling production; we may not receive any orders for our products; we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.



Contact:

Media Contact:

Emerson Gerard Associates, Inc.

Jerry Jennings, 561-881-7318

[e-mail]



Investor Contact:

The PMH Group

Paul Holm, 212 496 7238

[e-mail]

[lowkatmai]

Antwort auf Beitrag Nr.: 24.842.424 von the key am 25.10.06 13:10:50

Hi,

vor dem Lebed Push wurde halt Wind gemacht (gerade bei den Amis), als würde es morgen keine Aktien mehr geben. Jetzt gibts aber mehr als genug und die noch zu einem relativ günstigen Preis!

MK gerade mal etwas über 6 Mio US$.


Steige heute ein.


l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.843.872 von lowkatmai am 25.10.06 14:27:46

Hi,

bei 0,023 dabei.


l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.845.830 von lowkatmai am 25.10.06 15:46:16

Hi,

war wohl nocht etwas zu früh.

Fallt weiter in RIchtung 0,02.


ZUrück zum ATL?

l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.845.995 von lowkatmai am 25.10.06 15:51:29

Hi,

Mist leider wirklich zu früh.

Denke ATL bei 0,016 könnte auch noch kommen. Nur noch gut 0,006 bis dahin.

Aber warten wir einfach ab.


l

[the key]

PLRS: J.M. Dutton Ups to Speculative Buy from Neutral; Sets Tgt @ $0.06; Analyst Notes

Wednesday, October 25, 2006 07:21 ET

Issuer: Pluristem Life Systems Inc (OTCBB: PLRS)

Analyst Firm: J.M. Dutton & Associates, LLC

Ratings Action: UPGRADE

Current Rating: Speculative Buy (from Neutral)


Target Price: $0.06

Analyst Comments: The firm points out that PLRS stock overhang from a previous overhang has been worked through and the common stock could now significantly appreciate as this selling pressure is reduced. Because they continue to be enamored by Pluristem's technology they have, therefore, revised their investment rating to Speculative Buy with a 12-month price target of $0.06.

This rating information was reported by J.M. Dutton & Associates, LLC

[lowkatmai]

Antwort auf Beitrag Nr.: 24.857.111 von the key am 26.10.06 00:06:14

Hi,

J.M. Dutton & Associates, LLC

werden die nicht von PLRS bezahlt?


Target Price: $0.06

ist ja nicht gerade überwältigend.
Gut, besser als DAUSEND zu schreien sind seriöse Kursziele auf jeden Fall.
Aber in 12 Monaten 0,06 da kann ich ja auch einen "sicheren" Dax-Wert kaufen.

l

[the key]

Antwort auf Beitrag Nr.: 24.862.668 von lowkatmai am 26.10.06 11:47:40

dann kauf einen Dax Wert

[lowkatmai]

Antwort auf Beitrag Nr.: 24.865.170 von the key am 26.10.06 13:53:41

Hi,

hab' ich schon und zwar alle (ETF)

l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.866.311 von lowkatmai am 26.10.06 14:43:58

Hi,


hier was von Lebed (24.10):

PLRS just announced this morning that 98% of the convertible debentures are now gone!!!!!!!!!

This has been the only thing that has been holding PLRS stock down!!!!!!!

We could see PLRS explode this morning!!!!!!!!

-----

My firm Lebed Biz LLC has been compensated by a third-party (Zigel and Ross), $25,000 cash for a one-month PLRS investor relations contract. Back in 2004 I was compensated by a third-party 25,000 free-trading shares of PLRS for a one-month PLRS investor relations contract which has since expired. I already sold all of these shares. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: www.lebed.biz/disclaimer.htm

Jonathan Lebed
Lebed.biz
Staff


Habe mich dort angemeldet, da wird man zugeballert mit Mails! Grausam. Der Push bei PLRS ist bei denen jedenfalls schon durch!!


l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.873.419 von lowkatmai am 26.10.06 19:25:31

Hi,

lebed push is over! Sieht man ja gerade.

Was sonst noch die nächste Zeit kommt, keine Ahnung.

Tschö

l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.874.088 von lowkatmai am 26.10.06 19:48:29

Hi,

sieht so aus als kommen heute noch die ATL (bei gut 0,018)

Grausamer Kursverlauf


l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.874.546 von lowkatmai am 26.10.06 20:03:45

Hi,

hier der neue Zock von lbed:




After the HUGE success we had with PLRS I got so many emails and phone calls about companies that I should make my next big pick and I decided on BOCX.

BOCX has what I believe is the BEST product in the world for detecting cancer.

Currently the most common test used to detect cancer is the PSA test and BOCX has just proven that their RECAF test detected twice the amount of cancers.

BOCX's technology is patented and nobody else has anything like it.

BOCX has already signed a deal with ABT a $74 billion NYSE traded company. ABT will be commercializing products using BOCX's technology.

More than 10 million people are diagnosed with cancer every year, and it is estimated that there will be 15 million new cases every year by 2020. The chance of cure increases substantially if cancer is detected early.

BOCX's upside potential is astronomical at these levels!!!

Start researching BOCX right now!!! I will start sending out more information on the company tonight once I get back from LA. Be ready for tonight, tomorrow, this weekend and next week!!!!!!

-----

My firm Lebed Biz LLC has been compensated by a third-party (Onyx Consulting), $25,000 cash for a one-month BOCX investor relations contract. My firm Lebed Biz LLC has been compensated by a third-party (Zigel and Ross), $25,000 cash for a one-month PLRS investor relations contract. Back in 2004 I was compensated by a third-party 25,000 free-trading shares of PLRS for a one-month PLRS investor relations contract which has since expired. I already sold all of these shares. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: www.lebed.biz/disclaimer.htm

Jonathan Lebed
Lebed.biz
Staff




Also kaufen und zwar schnell

l

[the key]

Antwort auf Beitrag Nr.: 24.753.645 von the key am 21.10.06 01:41:50

[lowkatmai]

Antwort auf Beitrag Nr.: 24.880.166 von the key am 27.10.06 04:09:34

HI,

so spät noch am Computer?

Chart sieht grausam aus. Schluss auf Tagestief.


l

[lowkatmai]

Hi,

hier eine der letzten Emails (da kommen am Tag 5-10!!!9 von lebed.

"A couple of people emailed me asking how I could claim PLRS was a big success.

Hello?? From the opening price Monday of last week of $0.023 to the high on the following Wednesday of $0.032 it gained 39%!!!

Then when it dipped to $0.0215 on Thursday I said it was a great buying opportunity and earlier this week it ran to $0.032 again. That is another gain of 49%!!!

You don't think this was a major success?? I certainly do!

I believe BOCX could make similar short-term gains. Although I must stress my past performance should not be used as an indicator of future returns.

Look at BOCX's long-term chart. This stock has been known to EXPLODE when major developments are announced. Back in 2004 it went from approximately $0.25 to $4 in just TWO DAYS!!!

I once again believe PLRS is a great buying opportunity right now!!! I believe it will make another short-term run and the big winners will be those who hold PLRS for the long-term.

I announced BOCX today as my new big pick because I believe this company fits in perfectly with PLRS.

BOCX has what I believe to be the best technology in the world for detecting cancer early and PLRS is using Adult Stem Cells from Cord Blood to create new treatments for cancer!!!

I am very confident that PLRS and BOCX will save millions of lives in the future!!!

Please don't invest into either companies because of me. In no way do I recommend that you buy or hold either of these stocks. You could lose all of your money in these stocks.

-----

My firm Lebed Biz LLC has been compensated by a third-party (Onyx Consulting), $25,000 cash for a one-month BOCX investor relations contract. My firm Lebed Biz LLC has been compensated by a third-party (Zigel and Ross), $25,000 cash for a one-month PLRS investor relations contract. Back in 2004 I was compensated by a third-party 25,000 free-trading shares of PLRS for a one-month PLRS investor relations contract which has since expired. I already sold all of these shares. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: www.lebed.biz/disclaimer.htm

Jonathan Lebed
Lebed.biz
Staff"


l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.883.866 von lowkatmai am 27.10.06 10:41:32

Hi,

ledeb push endgültig durch! Jetzt kann die Konsolidierung kommen.


l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.890.766 von lowkatmai am 27.10.06 15:44:54

Hi,

Frage ist jetzt, was kommt an News die nächste Zeit bei PLRS?

Oder pusht lebed oder andere Jungs den Wert nochmal so gnadenlos?


l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.891.135 von lowkatmai am 27.10.06 15:58:04

Hi,

ATL kommt heute!! Hab ne Kauforder drinn, mal schauen ob die zum Zug kommt.


Jetzt wird ja richtig geschmissen bei PLRS.

l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.891.135 von lowkatmai am 27.10.06 15:58:04

Hi,

ATL kommt heute!! Hab ne Kauforder drinn, mal schauen ob die zum Zug kommt.


Jetzt wird ja richtig geschmissen bei PLRS.

l

[lowkatmai]

Antwort auf Beitrag Nr.: 24.891.491 von lowkatmai am 27.10.06 16:09:17

Hi,

aktuell nur 2 neue Mails zu BOCX von lebed. (Big Break Out next week ....)

Nix zu PLRS.

Mach jetzt Feierabend. Tschö.

Kauflimit steht


l

[joelu]

Threadtitel sollte ehr umbenannt werden in:

PLRS, der nächste Halbierer!!!

so eine scheiße! hänge nach meinem hochprofitablen PTSH zock nämlich jetzt hier fest.

zu 0,021$ gekauft, zu 0,02$ nachgekauft und nochmals zu 0,0196$. jetzt reicht es aus. wol wollen die das teil noch hinprügeln.

oder ist da was schlechtes im anmarsch? wer weiß was?

[joelu]

Antwort auf Beitrag Nr.: 24.907.778 von joelu am 28.10.06 09:39:51

nachbörslich ist ein trade mit 1.000.000 teilen zu 0,019$ durchgelaufen:

Time & Sales
Price Size Exch Time
0.019 1000000 OBB 16:06:00
0.0185 5000 OBB 15:57:15
0.0185 13227 OBB 15:55:53
0.0185 11773 OBB 15:55:53
0.0185 12500 OBB 15:54:02
0.0185 5000 OBB 15:52:51
0.0189 10000 OBB 15:48:32
0.0189 25000 OBB 15:48:30
0.0189 25000 OBB 15:48:27
0.0185 100000 OBB 15:46:27
0.0185 200000 OBB 15:45:53
0.0182 138370 OBB 15:45:23
0.0182 27000 OBB 15:45:23
0.0182 3200 OBB 15:44:13
0.0182 70000 OBB 15:43:57
0.0183 60000 OBB 15:42:53
0.0184 100000 OBB 15:42:22
0.0188 28800 OBB 15:40:18
0.0188 71200 OBB 15:40:18
0.0188 68800 OBB 15:39:17
0.0188 60000 OBB 15:30:25
0.0188 40000 OBB 15:30:12
0.0188 77000 OBB 15:29:11
0.0189 65000 OBB 15:28:37
0.0188 60000 OBB 15:23:30
0.0188 5000 OBB 15:22:34
0.0185 5000 OBB 15:00:17
0.0185 80000 OBB 14:59:42
0.0185 50000 OBB 14:55:54
0.0185 70000 OBB 14:54:40


ich denke, montag geht es wieder hoch über die 0,02$. werde dann auch zeitnah in der gewinnzone aussteigen.

[joelu]

Antwort auf Beitrag Nr.: 24.908.241 von joelu am 28.10.06 10:03:51

wahrscheinlich war es auch das filing von gestern, was einige zum abschenken ermutigte:

...Other Events

On October 24, 2006 we announced that over 98% of the $3,000,000 in convertible debentures that we issued on April 3, 2006 have been converted to common stock in our company. This allows us considerably more financing flexibility because until over 75% of the debentures were converted to common stock, we were prevented from pursuing certain types of financing arrangements and our assets

[the key]

Antwort auf Beitrag Nr.: 24.908.390 von joelu am 28.10.06 10:10:39

das war bereits bekannt.
Und gibt nur an das die Aktion abgeschlossen ist.
Aus sicherer Quelle weiß ich auch das ein Großteil der neu ausgegebenen Aktien in feste Hände gelangt sind.
Mal abwarten wie es weitergeht

[joelu]

Antwort auf Beitrag Nr.: 24.917.370 von the key am 28.10.06 13:35:19

das würde bedeuten, dass es nächste woche bedeutend aufwärts gehen sollte!

0,025$ sollten dann drin sein...


könnte mir sogar vortstellen, dass gute news kommen und man das teil vorher nochmal stark heruntergeprügelt hat...

[lowkatmai]

Hi,
was von den Amis /i-Hub)


Posted by: idahoseb
In reply to: up-down who wrote msg# 867 Date:10/29/2006 8:45:31 PM
Post #of 890

As much as I hate to say it, this stock is still in a "Death Spiral". I went thru this in ASTM when the CEO financed a convertible loan with some guys in Colorado back in 1999. What the loan sharks want is a low price so they can get a lot of stock in return. I believed in the technology and kept buying ASTM down to 25 cents from $2.00. My portfolio which was only ASTM went from $15k down to $6k, but when the death spiral was over they pumped the stock to $8, then shorted.
If you read the last quarterly for PLRS you willl see that the infamous market maker "NITE" is one of the financers here. I expect a run to about 40 to 70 cents.
Considering the awesome stem cell breakthru PLRS has made, this will still be cheap at a market cap of $120 to 200 million. ASTM is moving up on news that is horse and buggy compaired to what PLRS has done.
Best to remember we are swimming with sharks here.



l

[joelu]

puhhh, da tut sich bisher nichts mehr....

wenigstens scheint das ding die bremse gefunden zu haben. unter einem mini-umsatz vegetieren wir knapp über dem sk vom freitag.

hoffentlich ist das jetzt mal wieder der turnigpoinz nach den abschenkorgien der letzten tage...


Time & Sales most recent next page
Rec. Time Action Price Volume
10:45:02 AM Trade 0.019 5000
10:44:48 AM Trade 0.019 5000
10:44:48 AM Bid 0.0189 5000
10:44:06 AM Trade 0.0192 50000
10:41:44 AM Trade 0.019 50000
10:41:04 AM Trade 0.019 10000
10:40:48 AM Trade 0.0186 26900
10:40:48 AM Trade 0.0186 100000
10:40:42 AM Trade 0.0192 10000
10:39:48 AM Trade 0.019 5000
10:39:24 AM Trade 0.0192 3000
10:39:12 AM Trade 0.019 10000
10:39:10 AM Bid 0.019 5000
10:38:46 AM Trade 0.019 5000
10:38:42 AM Ask 0.0192 5000
10:35:40 AM Trade 0.0195 15000
10:35:38 AM Trade 0.019 22700
10:35:22 AM Bid 0.019 10000
10:29:24 AM Trade 0.019 70200
10:29:22 AM Trade 0.019 4790
10:29:22 AM Trade 0.019 5000
10:29:20 AM Trade 0.019 20000
10:29:06 AM Trade 0.019 28000
10:29:06 AM Bid 0.019 5000
10:29:04 AM Trade 0.019 77000
10:28:56 AM Bid 0.019 10000
10:28:36 AM Ask 0.0195 5000
10:23:32 AM Trade 0.019 25000
10:22:46 AM Trade 0.019 50000
10:22:44 AM Trade 0.019 50000
10:13:16 AM Ask 0.0199 5000
10:10:20 AM Ask 0.0195 5000
10:09:16 AM Trade 0.02 500
10:08:32 AM Trade 0.0192 10000
10:08:20 AM Trade 0.0192 52000
10:08:20 AM Bid 0.019 5000
10:07:46 AM Bid 0.0192 5000
10:02:58 AM Trade 0.02 46650
10:00:34 AM Trade 0.019 57200
9:58:10 AM Trade 0.0195 10000
9:58:10 AM Bid 0.019 5000

[lowkatmai]

Antwort auf Beitrag Nr.: 25.013.092 von joelu am 30.10.06 16:46:12

Hi,

der Lebed Push ist erst mal verarbeitet. (Hoffentlich oder gibts nocht Enttäuschte die jetzt schmeissen?)

Mal sehen was jetzt an Substanz von PLRS kommt.


l

[lowkatmai]

HI,

auch der neue Push von Lebed:

BOCX Biocurex Inc

läuft aktuell (noch) nicht.

Zu PLRS meldet er sich gar nicht mehr. Gut so?

Gabs zu den Hedge Fonds Managern noch was?
Gab diesen big report zu PLRS und wo kann man diesen einsehen?
War PLRS der biggest percentage gainer of the year für Ledeb?

"PLRS will be giving a presentation to hedge funds that have invested into the company. As soon as the meeting is over, probably around 1PM, I will be sending out an alert going over everything I learned at the meeting!

My big PLRS report that I have been writing for the past week will be coming out Friday morning before the open.

Therefore, even at $0.23, I believe PLRS would still be undervalued!!!!!

Now you understand why I believe PLRS will become our biggest percentage gainer of the year!!!!!"



l

[lowkatmai]

Hi,


"HAIFA, Israel, Oct 31, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBB: PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA by the end of the 4th quarter Of 2006. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.

Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company's innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).

In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem's Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.

In the upcoming Pre-IND filing, Pluristem will present to the FDA CBER team the results of an additional agreed upon pre-clinical Animal trial. This additional pre-clinical animal trial will be performed on immune-deficient irradiated NOD-SCID mice which will be co-implanted with un-purified human umbilical cord blood cells and PLX-I. The conclusions will be held in comparison to Pluristem's published Pre-clinical results that used CD34+ purified from human umbilical cord blood cells. This additional trial will determine the final structure of the pre-clinical data required for FDA approval of the IND application.

Mr. Zami Aberman, Pluristem CEO, stated: "We would like to thank the CBER team for the very productive discussion. We expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults. I believe that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase I trials."

About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

www.pluristem.com



l

[lowkatmai]

Antwort auf Beitrag Nr.: 25.036.396 von lowkatmai am 31.10.06 15:09:55

Hi,

relativ viel:
Pre-Pre- in der PR.


moving to Phase I

dauert ja auch noch.

derzeit erst:

pre-clinical animal trial will


Da fließt also noch sehr, sehr viel Wasser den Rhein runter, bis was konkretes kommt. (Jahre!!)

Hoffentlich werden die übernommen oder verkaufen ihr Patent/Technologie.


l

[lowkatmai]

Hi,

die Börse sieht auch, dass das noch ganz, ganz lange dauert bei PLRS.

RT

0,0193



l

[lowkatmai]

Antwort auf Beitrag Nr.: 25.037.905 von lowkatmai am 31.10.06 16:00:18

Hi,

eventuell gibt es ja danach News:



PLRS is going to have a series of meetings with potential investors on Nov 13th and 14th in New York.


l

[lowkatmai]

Hi,

sehen auch die Amis so, dass es noch ein wneig dauert (Jahre) bis was kommt von PLRS



Posted by: stocktalkpa

Date:10/31/2006 1:17:05 PM


I agree with the consensus view that this is a good, albeit risky investment. The potential from this pps level is huge & if the technology is as innovative as the company believes a buy-out is a possibility. I personally don't think it will be five years to get a product to market. If they are successful with their product development efforts and proceed along the current path it will be years, but probably not five years.

How the company approaches future financing will have a big impact on the pps.


und das der Ledeb Push vorbei ist (Gut, dafür muss man keine Schnellmerker sein!)

Posted by: MACHIAVELLI01

Date:10/31/2006 1:32:40 PM


stocktalkpa this is unfortunatly the end result of the lebed pump which hurts pps credibility for awhile. From here out convertable
financing will be the demon to watch for.


Ist hier noch jemand dabei?


l

[lowkatmai]

HI,

Posted by: manny t
In reply to: None Date:11/1/2006 8:08:00 AM
Post #of 933

This looks good,

Pluristem Appoints Yaky Yanay Chief Financial Officer
Wednesday November 1, 7:30 am ET


HAIFA, Israel--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB: PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, today announced that the Board of Directors has appointed Yaky Yanay as Chief Financial Officer and Company Secretary, replacing Yossi Keret in this position.
ADVERTISEMENT


Prior to joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision System Ltd (EVSNF.OB) a company engaged in automatic optical inspection. He has had extensive experience in financing and management of technology companies, and played a major role in planning and executing a turn around plan of Elbit Vision System, including the completion of three acquisitions and raising more than $20 million, resulting in a tripling of the company's revenues and its attaining profitability.

Mr. Yanay began his financial career at Ernst & Young Israel in 1999, where he served as a manager of audit groups of the technology sector. He joined Ernst & Young's financial team after serving in the Israeli Ministry of Foreign Affairs since 1993.

Mr. Yanay holds a bachelor's degree with honor in business administration and accounting from the college of management studies in Rishon Le Zion, Israel and is a Certified Public Accountant in Israel.

Commenting on the nomination, Mr. Zami Aberman, Pluristem CEO, stated," We are very pleased that Yaky has decided to join our team. I believe that he is the right man at the right time to help enable Pluristem to accomplish its plans of becoming a leading provider of cell therapy products that do not require a match, and target the critical global shortfall of matched tissue for bone marrow transplantation - an unmet need of more than 100,000 patients annually. I would like to thank Yossi Keret for his devoted service and contributions during the past three years and wish him successes in his new challenges."



l

[lowkatmai]

HI,

sieht ja ganz , ganz übel aus hier.


Wirklich nix dahinter bei PLRS?

Lebed war jedenfalls erfolgreich, die Aktie gnadenlos abzupushen.

Jeder Daxwert hat derzeit mehr Power.


l

Halte mich aber jetzt zurück, da anscheinend niemand mehr hier dabei ist.

[joelu]

doch, ich bin noch dabei. und zwar volles rohr. hätte nicht gedacht, dass die soweit angeprügelt werden würden!

habe jedoch den vorteil, dass ich bei 0,0204$ schon wieder pari verkaufen kann... die werdenw ir hoffentlich als technische reaktion nochmals sehen...

[joelu]

HAIFA, Israel- October 24, 2006 - Pluristem Life Systems, Inc. (OTCBB: PLRS) today announced that it has completed the conversion to common stock of 98% of the $3,000,000 in convertible debentures that were issued on April 3, 2006 . The total number of outstanding common shares is now about 254 million shares.


mk derzeit 254.000.000 x 0,0175$ = 4.445.000$

andere unternehmen sind deutlich höher bewertet!

[lowkatmai]

Antwort auf Beitrag Nr.: 25.078.151 von joelu am 02.11.06 11:30:07

Hi,

MK 4.445.000$

ist wirklich nicht hoch, kann die Wertigkeit der Patente/Verfahren von PLRS aber nicht abschätzen.

Ich denke da ist sogar mehr als eine technische Reaktion vom derzeitigen ATL drin.

Bin leider viel zu früh rein und dachte der Push von Lebed läuft nicht ganz so gnadenlos verhehrend. (Für ihn ja erfolgreich!)

l

[joelu]

Antwort auf Beitrag Nr.: 25.080.313 von lowkatmai am 02.11.06 13:33:20

nichts wäre mir lieber, als wenn du recht hättest!!!

wenn ich sehe, welche schrottbuden schon mks von über 20.000.000$ haben....

dann stünden wir bei 254.000.000 aktien schon bei 0,07874$...


naja, vorbörslich leicht nach oben:

spanne: 0,0171$ - 0,0178$

[joelu]

Antwort auf Beitrag Nr.: 25.081.913 von joelu am 02.11.06 15:05:18

ask wieder runter: 0,0174$...so wird das nichts

[lowkatmai]

Antwort auf Beitrag Nr.: 25.082.483 von joelu am 02.11.06 15:31:46

Hi,

gerade erreicht All-TIme-Low!!

0,016!

Grausam, grausam.

Aber wie schon gepostet, das dauert noch Jahre bis hier Substantiell was kommt, vorher nur Fantasie und Gepushe.


l

[joelu]

Antwort auf Beitrag Nr.: 25.082.763 von lowkatmai am 02.11.06 15:41:45

hi zurück!

sollten die 0,016$ halten, hätten wir einen doppel-bottom. das waäre dann positiv zu werten!

halten die 0,016$ nicht, dann aber "gute nacht" !!!

[lowkatmai]

Antwort auf Beitrag Nr.: 25.082.962 von joelu am 02.11.06 15:47:58

HI,

bislang halten doe 0,016.

Der neue Push von Lebed kommt übrigens gerade ins laufen

BOCX RT 0,94x


l

[joelu]

Antwort auf Beitrag Nr.: 25.083.225 von lowkatmai am 02.11.06 15:57:41

ich denke, der wollte ma freitag nochmal was zu PLRS bringen?

[lowkatmai]

Antwort auf Beitrag Nr.: 25.083.492 von joelu am 02.11.06 16:06:39

Hi,

nö bzw. keine Ahnung
Aktueull wird BOCX gepusht


Heute schon 6 Emails bekommen. (Sind aktuell sicher schon 7!!)

Bislang erfolgreich

RT BOCX 0,94

Push hat glaube ich bei ca. 0,74 begonnen. Lebed hat sicher noch tiefer zugeschlagen und zusätzlich 25.000 eingesteckt.


l

[lowkatmai]

Antwort auf Beitrag Nr.: 25.084.210 von lowkatmai am 02.11.06 16:35:35

Hi,

ich denke die 0,016 halten nicht, aber nur ein Bauchgefühl.


l

[joelu]

Antwort auf Beitrag Nr.: 25.085.624 von lowkatmai am 02.11.06 17:36:21

nein, sie ziehen uns jetzt ganz brutal daas fell über die ohren, die 0,015$ wird wohl auch nicht halten!

Time & Sales most recent next page
Rec. Time Action Price Volume
12:39:08 PM Bid 0.0154 5000
12:36:54 PM Trade 0.0153 50000
12:36:38 PM Bid 0.0153 5000
12:36:22 PM Ask 0.0155 5000
12:36:20 PM Trade 0.0153 65000
12:36:14 PM Trade 0.0152 65000
12:34:00 PM Trade 0.0153 2500
12:33:32 PM Trade 0.0153 2500
12:33:30 PM Trade 0.0152 50000
12:32:12 PM Trade 0.0153 50000
12:31:32 PM Bid 0.0152 5000
12:31:28 PM Trade 0.0151 3500
12:30:46 PM Trade 0.0151 10000
12:30:28 PM Ask 0.0153 5000
12:30:08 PM Bid 0.0151 5000
12:30:08 PM Trade 0.0154 50000
12:30:04 PM Trade 0.0153 50000
12:29:46 PM Trade 0.0154 200000
12:29:40 PM Trade 0.0153 200000
12:29:24 PM Trade 0.0153 5000
12:28:58 PM Trade 0.0153 18000
12:28:32 PM Trade 0.0154 50000
12:28:26 PM Trade 0.0153 50000
12:28:06 PM Trade 0.0153 5000
12:27:54 PM Trade 0.015 5000
12:25:18 PM Ask 0.0154 5000
12:23:10 PM Trade 0.0155 4000
12:22:46 PM Trade 0.0153 63450

[pennystocker3]

...kommt jetzt endlich die kurzfristige bis langfristige Trendwende-Umkehrformation?????

...spätestens bei 0,0139 sollte der Kurs heftig drehen!!...kann allerdings schon heute bei 0,015 passieren!










penny....

[lowkatmai]

Antwort auf Beitrag Nr.: 25.088.131 von pennystocker3 am 02.11.06 19:34:01

Nabend,

könnte sein, dass jetzt die Trendwende kommt

Die 0,016 haben nicht gehalten, jedenfalls Intraday (hat mich mein Bauch nicht getrügt!)

Aktuell leicht über 0,016.

Mal schauen was noch zum Schluß kommt.

Bei den Amis sind die Boards ganz tot.


l


BOCX hat heute den Ausbruch Intraday gepackt. RT aber "nur" noch 0,95.
Da muss Lebed also noch mal richtig nachlegen mit dem pushen!!

[joelu]

puhhhhhhhhhhhhhhhh!!!!!

der umkehrtrend scheint eingeleitet!!!

ganz vaginales...ähhhh...marginales volumen, aber wir stehen wieder bei 0,017$. das ist zumindestens die brmese im abwärtstrend!

Time & Sales most recent next page
Rec. Time Action Price Volume
10:35:06 AM Trade 0.017 15000
10:35:02 AM Trade 0.017 29000
10:35:02 AM Trade 0.017 5000
10:34:26 AM Trade 0.0174 35000
10:33:34 AM Bid 0.017 10000
10:32:16 AM Trade 0.017 5000
10:32:14 AM Trade 0.017 16000
10:32:14 AM Bid 0.017 5000
10:32:14 AM Ask 0.0174 5000
10:31:00 AM Ask 0.017 5000
10:29:36 AM Trade 0.0174 3200
10:21:32 AM Trade 0.017 32000
10:21:26 AM Trade 0.017 40000
10:21:26 AM Ask 0.0174 5000
10:21:26 AM Ask 0.0178 5000
10:21:20 AM Trade 0.017 163300
10:21:14 AM Ask 0.017 5000
10:21:14 AM Trade 0.017 50000
10:20:54 AM Trade 0.017 10000
10:20:50 AM Bid 0.0165 5000
10:20:34 AM Trade 0.0165 10000
10:12:52 AM Trade 0.017 5445
10:08:42 AM Trade 0.017 50000
10:08:36 AM Bid 0.016 10000
10:07:00 AM Trade 0.017 10000
10:04:06 AM Bid 0.0165 5000
10:04:04 AM Ask 0.017 10000
10:03:58 AM Trade 0.0165 5000
10:00:38 AM Ask 0.0165 5000
10:00:34 AM Trade 0.016 5000
10:00:24 AM Trade 0.016 5000
9:59:44 AM Trade 0.016 29200
9:59:34 AM Bid 0.016 10000
9:59:24 AM Trade 0.016 5000
9:59:24 AM Trade 0.016 25000
9:59:24 AM Trade 0.016 55000
9:54:14 AM Trade 0.016 25000
9:54:14 AM Trade 0.016 25000
9:53:52 AM Bid 0.016 5000
9:53:52 AM Trade 0.016 20000
9:47:06 AM Bid 0.016 10000
9:45:24 AM Trade 0.016 12000
9:38:40 AM Ask 0.017 10000
9:38:26 AM Bid 0.016 5000
9:38:10 AM Ask 0.0174 5000
9:38:10 AM Trade 0.016 100000
9:34:32 AM Ask 0.016 10000
9:34:32 AM Bid 0.0158 5000
9:34:30 AM Trade 0.016 6250
9:34:24 AM Bid 0.016 6200

most recent next page
11:04:46 AM EST - Friday, November 3, 2006 - data is real-time

[joelu]

puhhhhhhhhhhhhhhhh!!!!!

der umkehrtrend scheint eingeleitet!!!

ganz vaginales...ähhhh...marginales volumen, aber wir stehen wieder bei 0,017$. das ist zumindestens die brmese im abwärtstrend!

Time & Sales most recent next page
Rec. Time Action Price Volume
10:35:06 AM Trade 0.017 15000
10:35:02 AM Trade 0.017 29000
10:35:02 AM Trade 0.017 5000
10:34:26 AM Trade 0.0174 35000
10:33:34 AM Bid 0.017 10000
10:32:16 AM Trade 0.017 5000
10:32:14 AM Trade 0.017 16000
10:32:14 AM Bid 0.017 5000
10:32:14 AM Ask 0.0174 5000
10:31:00 AM Ask 0.017 5000
10:29:36 AM Trade 0.0174 3200
10:21:32 AM Trade 0.017 32000
10:21:26 AM Trade 0.017 40000
10:21:26 AM Ask 0.0174 5000
10:21:26 AM Ask 0.0178 5000
10:21:20 AM Trade 0.017 163300
10:21:14 AM Ask 0.017 5000
10:21:14 AM Trade 0.017 50000
10:20:54 AM Trade 0.017 10000
10:20:50 AM Bid 0.0165 5000
10:20:34 AM Trade 0.0165 10000
10:12:52 AM Trade 0.017 5445
10:08:42 AM Trade 0.017 50000
10:08:36 AM Bid 0.016 10000
10:07:00 AM Trade 0.017 10000
10:04:06 AM Bid 0.0165 5000
10:04:04 AM Ask 0.017 10000
10:03:58 AM Trade 0.0165 5000
10:00:38 AM Ask 0.0165 5000
10:00:34 AM Trade 0.016 5000
10:00:24 AM Trade 0.016 5000
9:59:44 AM Trade 0.016 29200
9:59:34 AM Bid 0.016 10000
9:59:24 AM Trade 0.016 5000
9:59:24 AM Trade 0.016 25000
9:59:24 AM Trade 0.016 55000
9:54:14 AM Trade 0.016 25000
9:54:14 AM Trade 0.016 25000
9:53:52 AM Bid 0.016 5000
9:53:52 AM Trade 0.016 20000
9:47:06 AM Bid 0.016 10000
9:45:24 AM Trade 0.016 12000
9:38:40 AM Ask 0.017 10000
9:38:26 AM Bid 0.016 5000
9:38:10 AM Ask 0.0174 5000
9:38:10 AM Trade 0.016 100000
9:34:32 AM Ask 0.016 10000
9:34:32 AM Bid 0.0158 5000
9:34:30 AM Trade 0.016 6250
9:34:24 AM Bid 0.016 6200

most recent next page
11:04:46 AM EST - Friday, November 3, 2006 - data is real-time

[lowkatmai]

Hi,

die Trendwende bei PLRS?

Mal schauen was ich auf der Bio Messe in D ergiebt.

BOCX ist übrigens bei Lebed auch schon wieder durch!

Aktuell bei 0,85 (war aber schon über 1 US$ wie angekündigt!)

Nächster Push:


PYPR could become the subpenny play of a lifetime


l

[joelu]

Antwort auf Beitrag Nr.: 25.170.356 von lowkatmai am 06.11.06 09:39:03

roy-makaay: wir sehen diese woche wieder die 0,023$...

[lowkatmai]

Antwort auf Beitrag Nr.: 25.189.908 von joelu am 07.11.06 12:01:39

Hi,

na ja mal abwarten!

Aktuell ja gerade wieder durchwachsen. 0,017


l

[lowkatmai]

Antwort auf Beitrag Nr.: 25.194.662 von lowkatmai am 07.11.06 15:59:41

Hi,

durchwachsen ist noch geschönt: Horror wäre besser

Miniumsätze und Kurs schmiert gnadenlos ab


l

[lowkatmai]

Antwort auf Beitrag Nr.: 25.189.908 von joelu am 07.11.06 12:01:39

Hi,

wird ganz eng mt den 0,023!

Diese Woche wohl eher nicht!

[lowkatmai]

Antwort auf Beitrag Nr.: 25.252.934 von lowkatmai am 10.11.06 08:30:02

Hi,

völlig tote Hose:

Kurs, Umsatz, Boards (Amis + hier)


l

[lowkatmai]

HiHi,

Bio Messe in D hat wohl nichts ergeben!? Jedenfalls nicht kursmäßig.

Leider hat Lebed PLRS den Todesstoß verpasst. Kurzfristig!

Mal schauen was die angeblichen Investorengespräche in NY ergeben.


l

[lowkatmai]

HI,

alles nur ein großer Betrug bei PLRS?

Aktie nur noch mal hochgepusht von Lebed?

Ist ja absolut tot der Wert.


l

[midnight_1]

Antwort auf Beitrag Nr.: 25.391.414 von lowkatmai am 14.11.06 19:25:01

COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:

www.investorstockalert.com: Playstar Gains 26% and Pluristem 10%

Wellington, FL, Nov 15, 2006 (M2 PRESSWIRE via COMTEX) -- Investors's "Pre-Market Stock Watch Alert" this morning are Andover Medical, Inc. (OTCBB: ADOV), Playstar Corporation (OTC:PLYCF), CyberKey Solution's (PINKSHEETS: CKYS) ,Pluristem Life Systems, Inc. (OTCBB:PLRS), Medifast (NYSE:MED)
Andover Medical, Inc. (OTCBB :ADOV- http://finance.yahoo.com/q?s=ADOV.OB )

Closed down 4% yesterday. They announced the completion of a bridge financing, and the appointment of Robert A. Baron to its Board of Directors. AMI will use these proceeds and Mr. Baron's insight to further the company's business plan of acquiring organizations in the orthopedic Durable Medical Equipment, urodynamic diagnostic and treatment product industries.

On November 2, 2006, AMI filed a Form 8-K -- announcing the completion of a bridge financing for $673,000 -- to be used for working capital, including expenses incurred in connection with proposed acquisitions. AMI currently has letters of intent with four operating businesses to acquire all of their capital stock. AMI completed its bridge financing with a New York-based investment banking firm. A subsequent Series A financing is targeted to raise $5,000,000 with warrant coverage, if fully exercised, of an additional $15,000,000.

Newly named to AMI's board of directors, Mr. Robert A. Baron has served in executive business roles for 45 years, with successful exits to public companies. He is currently on the boards of organizations such as Exegenics, where he led the winning effort to secure an operating business opportunity; Hemobiotech, a biopharmaceutical business developing a blood substitute product; and NanoSensors, a company developing and manufacturing sensors and devices. Baron obtained a degree in business from the Ohio State University.

The securities sold and to be offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This release is not being used for the purpose of conditioning the market in the United States for any of the securities offered or sold.

About Andover Medical, Inc.

Andover Medical, Inc. (AMI) is seeking to take advantage of projected growth and evolving economies of scale arising from consolidation in the procedure specific Durable Medical Equipment (DME) and services segments of the orthopedic, podiatric, and urological physician care markets in the United States. The Company intends to establish a nationwide subsidiary network and plans to offer physicians the largest selection of competitively priced brand-name DME, and urodynamic diagnostic and treatment products.

Pluristem Life Systems, Inc. (OTCBB : PLRS- http://finance.yahoo.com/q?s=PLRS.OB )

Closed up 10% yesterday They announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA by the end of the 4th quarter Of 2006. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.

Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company's innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).

In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem's Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.

In the upcoming Pre-IND filing, Pluristem will present to the FDA CBER team the results of an additional agreed upon pre-clinical Animal trial. This additional pre-clinical animal trial will be performed on immune-deficient irradiated NOD-SCID mice which will be co-implanted with un-purified human umbilical cord blood cells and PLX-I. The conclusions will be held in comparison to Pluristem's published Pre-clinical results that used CD34+ purified from human umbilical cord blood cells. This additional trial will determine the final structure of the pre-clinical data required for FDA approval of the IND application.

Mr. Zami Aberman, Pluristem CEO, stated: "We would like to thank the CBER team for the very productive discussion. We expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults. I believe that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase I trials."

About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

www.pluristem.com

CyberKey Solutions, Inc (OTC : CKYS- http://finance.yahoo.com/q?s=CKYS.PK )

Closed up 4% yesterday.They announced that the Company has completed the testing of its MyFanKey on all of the next-generation video gaming systems. The MyFanKey is compatible with the Microsoft XBOX 360, as well as the soon-to-arrive Sony PS3 and Nintendo Wii.

CyberKey Solutions' MyFanKey can be used with the Microsoft XBOX 360, Sony PS3, and Nintendo Wii to store game and gamer information, as well as music, movies, and pictures. The digital serial number, which is placed on each CyberKey, is designed to be utilized in the future to work with major movie, music, and game content providers as they offer downloadable content. For example, users can rent a movie or game digitally from an online source, store it on the required MyFanKey, and have 72 hours to view the movie or play the game.

"This is an exciting time for us, as we have prepared ourselves to become players in one of the largest entertainment markets in the world. Our technology is at the front of a digital entertainment revolution. We believe that our secure USB flash drive solutions and impending web portal position us as a leader in the video game and entertainment industry," stated Jim Plant, CEO of CyberKey Solutions, Inc.

CyberKey Solutions, Inc. recently announced that it will be launching "Reach Out Program" for Company shareholders and interested investors. Due to the CyberKey Solutions' phenomenal growth and success, CyberKey is reaching out to the investment community in order to provide answers, dispel rumors, and better inform their shareholders and investors of interest.

About CyberKey Solutions, Inc.:

CyberKey Solutions, Inc. is currently fulfilling a $25 Million purchase order to various segments of the U.S. Government. CyberKey Solutions, Inc., based in St. George, Utah, partners with industry-leading manufacturers and distributors to deliver secure USB drive-based solutions to vertical markets and content owners, service providers and resellers. CyberKey's solutions solve real world issues in the entertainment, education, government, military, automotive, financial services and medical industries. CyberKey Solutions' technologies allow users to securely transfer large amounts of data, files and applications software from one electronic device to another while employing a patent-pending USB-based Digital Rights Management process. CyberKey's solutions create new opportunities for existing industries and applications. For more information, please visit CyberKey's website at http://www.cyberkeysolutions.com.

Playstar Corporation (OTC : PLYCF- http://finance.yahoo.com/q?s=PLYCF.PK )

Closed up 26% yesterday. They.announced that its advisors and legal team have advised them AGAINST a mandatory recall of the current PLYCF certificates as stated in today's press release.

The company feels that with its solid shareholder base this option is not necessary at this time.

This press release contains forward-looking statements involving risks and uncertainties including statements regarding the Company's future performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors which include, but are not limited to, our ability to leverage our technology, manage our growth, protect our intellectual property rights, attract new customers and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Medifast, Inc. (NYSE: MED- http://finance.yahoo.com/q?s=MED )

Closed up 9% yesterday. After the close they announced today third quarter results for the period ended September 30, 2006. For the quarter-ended September 30, 2006, Medifast reported revenue of $19.6 million, a 79% increase from $11 million in the third quarter of 2005. The Company reported net income of $1,490,000, or $0.12 per basic share ($0.11 per diluted share), versus $607,000 or $0.05 per basic share ($0.05 per diluted share) in 2005. Net income in the third quarter of 2006 was positively impacted by a tax benefit received as a result of the Company's investment in infrastructure in prior years. The third quarter of 2006 represented the Company's 28th consecutive quarter of profitability.

For the nine months ended September 30, 2006, Medifast reported revenue of $58.8 million, an increase of 97% from $29.9 million for the nine months ended September 30, 2005. The Company reported net income of $4.6 million, or $.37 per basic share ($.34 per diluted share), versus $1.6 million or $.13 per basis share ($.13 per diluted share) in 2005.

The Company had stockholders' equity of $27.2 million and working capital of $13 million at September 30, 2006, compared to $21.3 million and $9.6 million at September 30, 2005, respectively.

"We are pleased with the third quarter results, which were driven by our growing customer base within a multi-channeled business. Our customer acquisition strategy is driving brand awareness, which benefits our direct to consumer business and also drives customers and business opportunity leads into our direct sales network while fueling significant walk-ins to our new medically supervised clinics, which are now operational in test markets. We believe that our diverse infrastructure model, which does not rely on a single distribution method, will allow Medifast to benefit long term in the over $40 billion weight loss category. In a customer driven world, Medifast is positioned to handle the needs of all types of customers. Whether a person is looking to lose weight utilizing the advice of a nutritionist, the support of a health coach, share their experience with others in an online community or stay under medical supervision in a clinic or doctor's office, Medifast provides a program to cater to the individual needs of the customer," said Michael S. McDevitt, Medifast President and CFO.

"Medifast combines products and programs that have been clinically proven and trusted by physicians for over 25 years with a 21st century business model that recognizes that every consumer is an individual. Medifast is in the business of making people healthy in a time when we are experiencing an obesity epidemic in our country. Medifast is committed to providing a lasting solution for health and we are excited about expanding our programs to include broader recommendations for using Medifast for long term health as we move forward," stated Bradley T. MacDonald, Chairman and CEO.

2006 Financial Guidance

The company expects to generate revenue of $70 to $72 million for the year with after-tax earnings of $0.38 to $0.40 per diluted share.

About Investorstockalert.com

Investorstockalert.com is a Shazamstocks Inc. Company. Investorstockalert.com a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. Shazamstocks Inc.is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. Stock alerts goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. Stock alert provides all investors with the latest news, press releases, investment opinions, and research reports for all the companies highlighted on the site. Stock alert offers a free financial newsletter. To subscribe or get more information, visit our home page located at http://www.investorstockalert.com We offer many investor relations programs to public companies. To feature a company on our web site or in our daily Newsletter or Mid-Day Stock Alert, please contact Ken Weiner at 561-793-2665, or via email at [e-mail] Shazamstocks Inc. based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Shazamstocks Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Shazamstocks Inc is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securitiesviewed on Shazamstocks Inc sites or mentioned herein. Shazamstocks Inc has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion.

. PLRS - Pluristem Life Systems.- We will be compensated by a third-party (Zigel and Ross),up to $25,000 for profile coverage.We also own shares bought in the open market and will sell those shares ADOV - Andover Medical, Inc.- We have beem compensated by a third party Bymark Consulting eighteen thousand five hundred dollars for profile coverage.We hold a long position in CKYS Shazamstocks Inc. affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Shazamstocks Incwill not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Shazamstocks Inc undertakes no obligation to update such statements.

CONTACT: Ken Weiner Tel: [phone] e-mail: [e-mail] WWW: http://www.investorstockalert.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].




(C)1994-2006 M2 COMMUNICATIONS LTD

-0-


Search for Dun & Bradstreet reports on this company.

[lowkatmai]

Hi,

kurs weiterhin zum heulen

ATL


l

[lowkatmai]

HI,

gestern der Kurs war janoch gar nicht zum Heulen!!

Heute ist er zum Heulen


l

[lowkatmai]

Hi,

entweder PLRS ist eine Pommesbude oder Lebed hat wirklich ganze Arbeit geleistet und den Wert förmlich in Grund und Boden zu pushen.


l

[pennystocker3]

...Rebound heute auf mindestens 0.015 möglich!!!!!!





penny....

[lowkatmai]

Antwort auf Beitrag Nr.: 25.589.485 von pennystocker3 am 22.11.06 13:02:55

Hi,

so sicher wäre ich mir da nicht.

MK nur noch etwas über 3 Mio (bei ca. 250 Mio Aktien)

Nutzt aber scheinbar nix. Geld verbrannt wird derzeit noch wie wild und wohl auch die nächsten Quartale/Jahre.

Und nur einen neuer Push (durch wen auch immer) führt wohl auch nicht zu längerfristigen kursteigerungen.


l

[lowkatmai]

Antwort auf Beitrag Nr.: 25.597.136 von lowkatmai am 22.11.06 17:53:11

Hi,

kommt von PLRS in diesem Jahr noch was an News?

Geld verdienen werden die ja kommenden Jahre voraussichtlich nicht.
Alles wie schon gepostet im PrePrePrePreStadium.


Andere Meinungen/ Nwes?


l

[bobelle]

aus der aktuellen Wirtschaftwoche Nr. 49 vom 04.12.06 S. 128:

Hilfe bei Blutkrebs

Stammzellen » Das israelische Unternehmen Pluristem hat einen Weg gefunden, Knochenmarkstransplantationen für Blutkrebspatienten revolutionär effektiver zu machen. Die Hauptprobleme - Abstoßung und spärliche Vermehrung der Spenderzellen im Körper der Krebskranken - umgeht Pluristem mit dem Präparat PLX I aus Plazenta-Stammzellen. Während einer Schwangerschaft sorgt die Plazenta dafür, dass der mütterliche Körper den Embryo nicht abstößt. Wird PLX I Krebskranken gespritzt, akzeptiert deren Immunsystem Spenderzellen viel besser. Klinische Studien sollen bald beginnen, eventuell auch in Deutschland.

[jojoclemm]

NEW YORK, Dec 05, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (PLRS) today announced that it has been chosen to present at the annual meeting of the American Society of Hematology on December 10th in Orlando, Florida. Hematology experts from around the world will gather to discuss the latest developments in their field. Pluristem will present how it has overcome the major barrier resulting from pre-selection and separation of cord blood early hematopoietic stem cells (HSC), and their breakthrough process that improves engraftment of Umbilical Cord Blood when treating severe blood disorders.

The current methodologies used in HSC expansion protocols apply an enrichment stage of rare subpopulation source cells defined as CD34 positive cells. These CD34 cells are pre-selected from a large and mixed population of mononuclear cells. This process results in a substantial loss of source cells and targets a cell population that may not represent the earliest extractable population of HSC.

Zami Aberman, Pluristem CEO states, "Our ability to improve the engraftment of Umbilical Cord Blood in treating severe blood disorders, as presented recently in the ISEH conference in Minneapolis, has attracted attention in the hematology community. We are honored to have been chosen to present at this meeting of prestigious hematology experts. Our breakthrough process could lead to the wider use of Umbilical Cord Blood in bone marrow transplants and in treating various types of blood cancer benefiting 100,000 people annually."

The American Society of Hematology 48th Annual Meeting and Exposition is being held December 9-12, 2006 at the Orange County Convention Center, Orlando FL.

[jojoclemm]

Hallo,

habe mal mit limit 0,016$ geordert.

Ich verspreche mir einiges von den news die bis Jahresende kommen sollen:

HAIFA, Israel, Oct 31, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (PLRS) , a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA by the end of the 4th quarter Of 2006. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.
Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company's innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).

In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem's Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.

[lowkatmai]

Hi,

geht ja heute mal richtig was.

Bin zwar immer noch im Minus, aber nicht mehr so brutal.


l

[jojoclemm]

Antwort auf Beitrag Nr.: 26.026.956 von lowkatmai am 08.12.06 16:48:59

Hallo,

habe endlich eine ausführliche Bewertung gefunden (11.12.2006):

http://www.jmdutton.com/research/plrs/reports/plrs_report_12…



Gruß,

Jojo

[jojoclemm]

Antwort auf Beitrag Nr.: 26.026.956 von lowkatmai am 08.12.06 16:48:59

Auszug aus obiger Quellenangabe:

We believe that at Pluristem’s current market value of approximately $3.8 million, speculative, risk-tolerant, patient
investors could potentially see a significant upside relative to a downside of losing their entire investment. We believe this
is true despite the fact that Pluristem will need to raise additional capital in the spring of 2007. One only need examine
comparable companies such as Osiris Therapeutics, Inc. (NASDAQ:OSRI) and ViaCell (NASDAQ:VIAC), which have an
average value of approximately $375 million, to see the potential upside for Pluristem.
We are, therefore, maintaining our investment rating of Speculative Buy on the common stock of Pluristem with a 12-
month price target of $0.06.

[the key]

PLRS sollte die schlechten Tage hinter sich haben

[the key]

up

[URANI]

PLRS -- Pluristem Life Systems, Inc.
Com ($0.00001)

COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:

Pluristem Announces US FDA Acceptance of its Pre-IND Application to begin Pre-clinical Studies using PLX- I in Hematological Malignancies

NEW YORK, Feb 08, 2007 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBBLRS), a cell therapy company dedicated to the commercialization of non personalized stem cell products for a variety of indications, today announced that the United States Food and Drug Administration\'s (FDA) Center for Biological Evaluation and Research (CBER) accepted the Company\'s proposed Pre-Investigation New Drug (PreIND) for its PLX-I product in pre-clinical studies for the treatment of hematological malignancies.
PLX-I is an innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells. PLX- I is expected to be used to improve the engraftment of Umbilical Cord Blood when treating blood cancer and blood disorders. Acceptance of the Pre-IND document by the FDA precedes initiation of Phase I trials.

Zami Aberman, CEO of Pluristem, stated, "We are pleased to receive FDA\'s acceptance of our proposed pre-clinical studies, which may then pave the way for initiating human clinical trials during 2007. The meeting results prove the ability of our team to meet its target milestones. We are enthusiastic about the potential of our placental derived MSCs to become a superior alternative to bone marrow transplantation. We designed PLX-I to improve umbilical cord blood (UCB) engraftment, which if successful could be the key to resolving the global shortage of bone marrow tissue matching for transplantation."

"We believe that our placental derived Mesenchymal Stems Cells (MSCs), which are expanded using the Company\'s unique PluriX technology, may be useful for disorders other than hematological malignancies. Recently we announced that our research provided evidence that PLX cells are "immune privileged," which means they are invisible to a transplant recipient\'s immune system and do not trigger rejection enabling the use of PLX cells to treat other disorders."

About Pluristem

Pluristem Life Systems, Inc. is life sciences driven company that is developing and commercializing of non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. PLX-I, its first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

For more information, please visit our website: www.pluristem.com.

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that FDA\'s acceptance of our proposed pre-clinical studies may pave the way for initiating human clinical trials during 2007; that our placental derived MSCs have the potential to become a superior alternative to bone marrow transplantation; that our first products will be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation; that PLX-I could be the key to resolving the global shortage of bone marrow tissue matching for transplantation; that our unique PluriX technology may be useful for disorders other than hematological malignancies. Factors which may prevent these forward looking statements from coming to fruition include that our technology may not be validated as we progress further; our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company\'s latest 10-KSB filed with the SEC.

SOURCE: Pluristem Life Systems, Inc.




CONTACT: Pluristem Life Systems
Investor Contacts
Sr. VP Corporate Development
Dr. William Prather, 303-883-4954
[e-mail]
or
Segue Ventures LLC
Craig Bird, 215-885-4981
[e-mail]
Investors\' Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/
or
Media Contact
Emerson Gerard Associates
Jerry Jennings, 561-881-7318
[e-mail]


Copyright Business Wire 2007

-0-

KEYWORD: United States
Israel
North America
Africa/Middle East
INDUSTRY KEYWORD: Health
Biotechnology
Clinical Trials
Pharmaceutical

Search for Dun & Bradstreet reports on this c

[Exploser]

NEWS !!!!!!!!!!!!!1


February 14, 2007 - 7:04 AM EST

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

PLRS 0.035 0.00

Today 5d 1m 3m 1y 5y 10y



Pluristem Announces Private Equity Investment of $8M
Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy Company dedicated to the commercialization of stem cell products for a variety of indications, today announced that it has signed a binding term sheet with new investors for a private equity investment in the amount of $8,000,000. The first payment of funds totaling $1,250,000 has been received.

The investors will receive Pluristem restricted common stock at a price of $0.0125 per share and a warrant to purchase additional shares at an exercise price of $0.025 per share. The final agreement is expected to be completed by March 15, 2007.

Mr. Zami Aberman, CEO of Pluristem Life Systems stated: “We are delighted these new investors have shown their confidence in Pluristem. Our business strategy targets a potential $30 billion market by capitalizing on our proprietary PLacenta eXpanded (PLX I) and 3D PluriX™ technologies and our unique business model of “supply-on-demand” cells for a variety of clinical indications. This financing enables us to fund our activities for the next 2 years and generate the clinical data we believe will support the therapeutic effects of PLX-I in the treatment of hematological malignancies. In addition, we will explore the use of PLX-I in new clinical applications."

Pluristem developed PLX I as an allogeneic product, based on supplementing the umbilical cord blood cells with supportive cells that improve the effectiveness of engraftments and shorten recovery times. PLX I mesenchymal stem cells were proven to increase the umbilical cord blood stem cells effectiveness by 3-5 times in a pre-clinical study.

About Pluristem

Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor (PluriX™) mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the currently accepted standard procedure of bone marrow transplantation. PLX-I, Pluristem’ first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

For more information, please visit our website: www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that there is a $30 billion market potential for our products; that we expect to sign the final agreement for a $8,000,000 private placement by April,10, 2007; that we will be able to develop our “supply-on-demand” cells business model for a variety of clinical indications; and that this investment in the Company will enable us finance our activities for the next 2 years generating clinical data to support the therapeutic effects of PLX-I. Factors which may significantly change or prevent our forward looking statements from fruition include that the investors may not close the private placement or finance the remainder of the $8,000,000; we currently do not have sufficient authorized capital to complete the private placement in full and may be unable to increase our authorized capital; we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

Investors:
Pluristem Life Systems
Sr. VP Corporate Development
Dr. William Prather, 303-883-4954
[e-mail]
or
Segue Ventures LLC
Craig Bird, 215-885–4981
[e-mail]
Investors’ Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/
or
Media:
Emerson Gerard Associates
Jerry Jennings, 561-881-7318
[e-mail]



Source: Business Wire (February 14, 2007 - 7:04 AM EST)

News by QuoteMedia
www.quotemedia.com

[the key]

Antwort auf Beitrag Nr.: 24.691.528 von the key am 17.10.06 22:19:01

KZ $.056 mehr als erreicht
Das ganze in sage und schreibe 4 Monaten
von $ .028 auf $ .0929 im hoch.
Keine schlechte Ausbeute für die Leute ,die dabeigeblieben sind

[the key]

wow Kurs $ .14 da wurde mein KZ von $ .058 ja mehr als übertroffen

[larsuwe]

Hallo! Habe den Wert schon einige Zeit im Auge.Leider ist mir der Aktienkurs davongelaufen.Möchte noch einsteigen,aber der Aktienkurs kennt im Moment nur noch eine Richtung!Bin durch einen Börsenbrief auf das Unternehmen aufmerksam geworden.Also schreibe mir doch mal deine Meinung zum jetzigen Aktienkurs .Danke Ciao Lars!

[the key]

Antwort auf Beitrag Nr.: 28.823.903 von larsuwe am 15.04.07 14:24:00

mein KZ wurde mehr als erreicht. Aktuell ist das Risiko eines starken Rücksetzers sehr hoch...

[Gohar]

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease
6/14/2007

NEW YORK, Jun 14, 2007 (BUSINESS WIRE) --
Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that Pluristem's PLacenta eXpanded (PLX) cells have been demonstrated in vitro to have properties that the Company believes gives these cells the potential to treat Parkinson's Disease (PD). PLX cells are Pluristem's placental-derived mesenchymal stem cells (MSCs) that have been expanded in the Company's proprietary PluriX(TM) 3-D bioreactor.

Pluristem Chairman and CEO, Mr. Zami Aberman commented, "These preliminary results are encouraging. We intend to pursue further in vitro and in vivo studies with our PLX cells in the treatment of Parkinson's Disease as well as other disorders of the central nervous system. As a cellular therapy for PD and other neurodegenerative diseases, our PLX cells could be a readily available source of important enzymes, neurotransmitters and neurotrophic factors." Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.

The in vitro assay demonstrated that Pluristem's PLX cells can be differentiated into dopaminergic neurons. These neurons were found to have properties favorable to cells, which are known to be helpful in treating PD. These properties include the expression of tyrosine hydroxylase, and the finding of elevated nurr1 mRNA levels. Additionally, these neurons were found to secrete favorable neurotrophic factors such as GDNF, BDNF, IGF-1, and astrocytes markers such as S-100-b, GLUL, and GFAP.

About Parkinson's Disease

PD is a well characterized degenerative neurological disease whose symptoms are felt to be related to damage to dopamine-producing cells in the Central Nervous System (CNS). PD is felt to currently afflict approximately four million people in the western world which represents a multi-billion dollar market annually.

About Pluristem

Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).

Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.

Pluristem has offices and is incorporated in the USA with research and manufacturing facilities in Israel.

www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that "the Company believes PLX cells have the potential to treat Parkinson's Disease (PD); that We intend to pursue further in vitro and in vivo studies with our PLX cells in the treatment of Parkinson's Disease as well as other disorders of the central nervous system. As a cellular therapy for PD and other neurodegenerative diseases;that our PLX cells could be a readily available source of important enzymes, neurotransmitters and neurotrophic factors. And that Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

SOURCE: Pluristem Life Systems, Inc.

Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
[e-mail]
or
Strategic Growth International, Inc.
Richard Cooper, 212-838-1444
[e-mail]
or
Segue Ventures LLC
Craig Bird, 215-885-4981
[e-mail]
or
Investors' Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/
Copyright Business Wire 2007

[OttomanRosen]

October 22nd CEOcast Weekly Newsletter :


Pluristem Life Systems, Inc. (OTCBB: PLRS), a bio-therapeutics company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, last week announced that results from Fraunhofer Institute's ongoing in vivo study, utilizing Pluristem's proprietary PLacenta eXpanded (PLX) cells in treating ischemic stroke, showed initial promise as a potential therapy to treat stroke victims. PLX cells are stem cells obtained from the placenta and expanded using Pluristem's proprietary 3D PluriX technology. PLX cells were systemically injected into spontaneously hypertensive rats that had undergone middle cerebral artery occlusion, a commonly accepted ischemic stroke model, and showed a significant advantage in functional recovery over a control group that did not receive PLX cells. Pluristem believes these results, combined with favorable results of pre-clinical studies of its proprietary PLX cells for additional clinical indications being released next week at the 3rd World Congress on Regenerative Medicine in Leipzig, Germany, show great promise in treating millions of ischemic stroke patients, an estimated $4 billion market. Shares ended the week at $0.04, up one cent.

[xero1972]

achtung, achtung, rolle rückwärts !!! R/S 200:1 !!!




PLURISTEM LIFE SYS INC (U-PLRS) - News Release
Pluristem Announces a Reverse Stock Split in Conjunction With Its Application for Listing on the NASDAQ Capital Market

2007-11-08 08:00 ET - News Release



Company Website: http://www.pluristem.com
NEW YORK -- (Business Wire)

Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, degenerative and auto-immune indications, announced today that it intends to effect a 200 to 1 reverse stock split in conjunction with an application, previously filed, to list its shares on the NASDAQ Capital Market.

Mr. Zami Aberman, Pluristem’s President and CEO, commented, “The NASDAQ application is part of our strategy to strengthen Pluristem’s financial position, broadening the availability of our stock to both institutional and individual investors.”

About Pluristem

Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first product, PLX-I, is directed at resolving the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB).

Pluristem's products are derived from mesenchymal stromal cells (MSCs) obtained from the placenta and are not embryonic stem cells. They are expanded in the Company's proprietary PluriXTM 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multi-potent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompany transplantation.

Pluristem has offices in the USA with research and manufacturing facilities in Israel. www.pluristem.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, when we speak about our planned reverse stock split and our application to list our shares on the Nasdaq Capital Market, we are using forward-looking statements. We may not be approved for listing on Nasdaq. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.


Contacts:

Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
[e-mail]
Yaky Yanay, 972-74-710-7171
VP Finance and CFO
[e-mail]
or
CEOcast
Michael Wachs, 212-732-4300
[e-mail]


Source: Pluristem Life Systems, Inc.